Cedric Francois, Chief Executive Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 276,830 shares at $20.19 ($5.6M) on 2025-07-14, disclosed to the SEC on 2025-07-16.
Scheduled sale ($5.6M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.19 | 137,465 | $2.8M | 49.7% |
| 2 | $20.19 | 137,465 | $2.8M | 49.7% |
| 3 | $20.09 | 1,900 | $38K | 0.7% |
| Total | $20.19 avg | 276,830 | $5.6M | 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $226K | — | Filing → |
| APLS | SELL | 2025-08-29 | $12.7M | — | Filing → |
| APLS | SELL | 2025-07-18 | $797K | — | Filing → |